Download PDF
Horm Metab Res 2003; 35(9): 557-561
DOI: 10.1055/s-2003-42659
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Growth Hormone Therapy in GH-deficient Adults: Continuous vs. Alternate-days Treatment

C.  Giavoli1 , V.  Cappiello1 , S.  Porretti1 , C.  L.  Ronchi1 , E.  Orsi1 , P.  Beck-Peccoz1 , M.  Arosio1
  • 1Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Milan, Italy
Further Information

Publication History

Received 30 January 2003

Accepted after Revision 24 March 2003

Publication Date:
30 September 2003 (online)

Also available at
    Permissions and Reprints

Abstract

In the present report, we have compared 12 months of rhGH therapy given daily (D) at the beginning and then on alternate days (A) to 20 subjects with severe adult-onset GH deficiency (GHD). Aim of the study was to establish whether the lower frequency injection regimen is as effective as the daily dose. Measurements included: IGF-I levels, body composition (BF%), lipid profile, insulin sensitivity by homeostasis model assessment (HOMA-IR) and quantitative insulin check index (QUICKI), as well as thyroid function. Evaluation on A therapy was performed both 12 and 36 hours after the last rhGH injection. The final rhGH dose was 0.3 ± 0.1mg/day. During A, the dose used in D was doubled and given on alternate days. Recombinant hGH given during the A period induced changes in IGF-I levels, BF% and lipid profile comparable to daily treatment. HOMA-IR increased similarly after both regimens, though QUICKI did not significantly change. A significant reduction in serum FT4 levels occurred after both D and A therapy, so that an adjustment of L-T4 replacement dose in 5 of 20 patients was necessary. No differences were found in the various parameters after 12 and 36 hours post rhGH injection. In conclusion, rhGH therapy given on alternate days is clinically effective and may result in improved patient compliance. Monitoring glucose tolerance and thyroid function while on rhGH is essential.

Key words

GH Deficiency - GH Replacement - IGF-I - Insulin Resistance

References

  • 1 Bengtsson B-A, Johannsson G, Shalet S M, Simpson H, Sonksen P H. Therapeutic Controversy. Treatment of growth hormone deficiency in adults.  J Clin Endocrinol Metab. 2000;  85 933-937
    CrossrefPubMedGoogle Scholar
  • 2 Gómez J M, Gómez N, Fiter J, Soler J. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.  Horm Metab Res. 2000;  32 66-70
    PubMedGoogle Scholar
  • 3 Aimaretti G, Fanciulli G, Bellone S, Maccario M, Arvat E, Delitala G, Camanni F, Ghigo E. Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency.  Eur J Endocrinol. 2001;  145 267-272
    CrossrefPubMedGoogle Scholar
  • 4 Ekman B, Lindström T, Nyström F, Olsson A G, Toss G, Arnqvist H J. A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults.  Eur J Endocrinol. 2002;  147 49-57
    CrossrefPubMedGoogle Scholar
  • 5 Frasier S D. Human Growth Hormone [GH] in growth hormone deficiency.  Endocr Rev. 1983;  4 155-170
    PubMedGoogle Scholar
  • 6 Gunnarsson R, Wilton P. Clinical experience with Genotropin worldwide: an update March 1987.  Acta Paediatr Scand. 1988;  337 147-152
    PubMedGoogle Scholar
  • 7 Smith P J, Hindmarsh P C, Brook C GD. Contribution of dose and frequency of administration to the therapeutic effect of growth hormone.  Arch Dis Child. 1988;  63 491-494
    PubMedGoogle Scholar
  • 8 Drayer N M. The effect of increasing the frequency of growth hormone administration on lower leg length growth. In: Tanner JM (ed) Auxology 88: Perspectives in the Science of Growth and Developpement. London; Smith-Gordon 1989: 301-306
    Google Scholar
  • 9 MacGillivray M H, Baptista J, Johansson A. Outcome of a four year randomised study of daily versus three times weekly somatotropin treatment in prepubertal naïve growth hormone deficient children.  J Clin Endocrinol Metab. 1996;  81 806-1809
    PubMedGoogle Scholar
  • 10 Lucidi P, Laureti S, Santoni S, Lauteri M, Busciantella-Ricci N, Angeletti G, Santeusanio F, de Feo P. Administration of recombinant human growth hormone on alternate days is sufficient to increase whole body protein synthesis and lipolysis in growth hormone deficient adults.  Clin Endocrinol. 2000;  52 173-179
    CrossrefPubMedGoogle Scholar
  • 11 Chung Y S, Lee H C, Hwang S, Paik I K, Lee J H, Huh K B. Growth hormone replacement therapy in adults with growth hormone deficiency; thrice weekly low dose administration.  J Kor Med Sci. 1994;  9 169-178
    PubMedGoogle Scholar
  • 12 Amato G, Mazziotti G, di Somma C, Lalli E, de Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A. Recombinant growth hormone therapy in GH-deficient adults: a long term controlled study on daily versus thrice weekly injections.  J Clin Endocrinol Metab. 2000;  85 3720-3725
    CrossrefPubMedGoogle Scholar
  • 13 Ghigo E, Aimaretti G, Giannotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults.  Eur J Endocrinol. 1996;  134 352-356
    PubMedGoogle Scholar
  • 14 Segal K R, van Loan M, Fitzgerald P I, Hodgdon J A, van Itallie T B. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross validation study.  Am J Clin Nutr. 1988;  47 7-14
    PubMedGoogle Scholar
  • 15 Pichard C, Kyle U G, Bracco D, Slosman D O, Morabia A, Schutz I. Reference values of fat-free and fat masses by bioelectrical impedance analysis in 3393 healthy subjects.  Nutrition. 2000;  16 245-254
    CrossrefPubMedGoogle Scholar
  • 16 Friedwald W T, Levy R I, Frederickson D S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
    CrossrefPubMedGoogle Scholar
  • 17 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in men.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 18 Katz A, Nambi S S, Mater K. et al . Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.  J Clin Endocrinol Metab. 2000;  85 2402-2410
    CrossrefPubMedGoogle Scholar
  • 19 Khandawala H M, McCutcheon I E, Flyvbjerg A, Friend K E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.  Endocr Rev. 2000;  21 215-244
    CrossrefPubMedGoogle Scholar
  • 20 Binnerts A, Swart G R, Wilson J H. et al . The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition.  Clin Endocrinol. 1992;  37 79-87
    CrossrefPubMedGoogle Scholar
  • 21 Cuneo R C, Salomon F, Watts G F, Hesp R, Sonksen P H. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency.  Metabolism. 1993;  42 1519-1523
    CrossrefPubMedGoogle Scholar
  • 22 Baum H BA, Biller B MK, Finkelstein J S. et al . Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency.  Ann Intern Med. 1996;  125 883-890
    PubMedGoogle Scholar
  • 23 Weaver J U, Monson J P, Noonan K, John W G, Edwards A, Evans K A, Cunngham J. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults.  J Clin Endocrinol Metab. 1995;  80 153-159
    CrossrefPubMedGoogle Scholar
  • 24 Jørgensen J OL, Vahl N, Nyholm B. Substrate metabolism and insulin sensitivity following long-term growth hormone GH replacement therapy in GH-deficient adults.  Endocrinol Metab. 1996;  3 281-286
    PubMedGoogle Scholar
  • 25 Chrisoulidou A, Beshyah S A, Rutherford O, Spinks T J, Mayet J, Kyd P, Anyaoku V, Ayda A, Ariff B, Murphy M, Thomas E, Robinson S, Foale R, Johnston D G. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.  J Clin Endocrinol Metab. 2000;  85 3762-3769
    CrossrefPubMedGoogle Scholar
  • 26 Bonora E, Targher G, Alberiche M. et al . Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.  Diabetes Care. 2000;  23 57-63
    CrossrefPubMedGoogle Scholar
  • 27 Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of insulin resistance index as assessed by homeostasis model assessment.  Endocr J. 2001;  48 81-86
    PubMedGoogle Scholar
  • 28 Bastard J P, Robert J J, Jardel C, Buckert E, Grimaldi A, Haqinque I. Is quantitative insulin sensitivity check index a fair insulin sensitivity in humans?.  Diabetes Metab. 2001;  27 69-70
    PubMedGoogle Scholar
  • 29 de Fronzo R A, Tobin J D, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance.  Am J Physiol. 1979;  237 214-223
    PubMedGoogle Scholar
  • 30 Hwu C M, Kwok C F, Lai T Y, Shih K C, Lee T S, Hsiao L C, Lee S H, Fang V S, Ho L T. Growth Hormone [GH] replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience.  J Clin Endocrinol Metab. 1997;  82 3285-3292
    CrossrefPubMedGoogle Scholar
  • 31 Svensson J, Fowelin J, Landin K, Bengtsson B A, Johansson J O. Effect of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults.  J Clin Endocrinol Metab. 2002;  87 2121-2127
    CrossrefPubMedGoogle Scholar
  • 32 Quon M J. Editorial: Limitation of the fasting glucose to insulin ratio as an index of insulin sensitivity.  J Clin Endocrinol Metab. 2001;  86 4615-4617
    CrossrefPubMedGoogle Scholar
  • 33 Porretti S, Giavoli C, Ronchi C, Lombardi G, Zaccaria M, Valle D, Arosio M, Beck-Peccoz P. on behalf of Ely Lilly & Co. B9R-EW-GDED Italian Study Group . Recombinant Human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T4 replacement therapy become mandatory?.  J Clin Endocrinol Metab . 2002;  87 2042-2045
    CrossrefPubMedGoogle Scholar

P. Beck-Peccoz, M.D.

Institute of Endocrine Sciences · Ospedale Maggiore IRCCS

Pad. Granelli · Via F. Sforza, 35 · 20122 Milan · Italy

Phone: +39-20-50 32 06 07

Fax: +39-20-50 32 06 05 ·

Email: paolo.beckpeccoz@unimi.it

      >